Unity Biotechnology Analyst Ratings
Unity Biotechnology Analyst Ratings
While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a upgraded with a price target of $0.00 to $0.00. The current price Unity Biotechnology (UBX) is trading at is $1.94, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2023 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 11/14/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 08/09/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 06/26/2023 | 3.09% | Wedbush | $3 → $2 | Downgrades | Outperform → Neutral |
| 05/31/2023 | 415.46% | Roth MKM | → $10 | Initiates Coverage On | → Buy |
| 05/26/2023 | 209.28% | Citigroup | $5 → $6 | Maintains | Buy |
| 05/10/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 04/25/2023 | 54.64% | Wedbush | $5 → $3 | Maintains | Outperform |
| 03/28/2023 | 209.28% | Mizuho | $12 → $6 | Maintains | Buy |
| 03/28/2023 | 157.73% | Wedbush | $35 → $5 | Maintains | Outperform |
| 03/28/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 03/28/2023 | 157.73% | Citigroup | $15 → $5 | Maintains | Buy |
| 03/16/2023 | 1704.12% | Wedbush | → $35 | Reiterates | → Outperform |
| 03/16/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 02/15/2023 | 415.46% | HC Wainwright & Co. | → $10 | Maintains | Buy |
| 11/16/2022 | 518.56% | Mizuho | $80 → $12 | Maintains | Buy |
| 11/09/2022 | 415.46% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 11/02/2022 | 1755.67% | Wedbush | $4 → $36 | Maintains | Outperform |
| 08/16/2022 | 312.37% | Mizuho | $7 → $8 | Maintains | Buy |
| 08/15/2022 | 312.37% | Citigroup | $5 → $8 | Maintains | Buy |
| 05/17/2022 | 157.73% | Citigroup | $6 → $5 | Maintains | Buy |
| 01/04/2022 | 106.19% | Roth Capital | → $4 | Upgrades | Neutral → Buy |
| 11/10/2021 | 260.82% | Mizuho | $5 → $7 | Upgrades | Neutral → Buy |
| 06/28/2021 | — | Citigroup | Upgrades | Sell → Buy | |
| 06/07/2021 | 518.56% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 08/18/2020 | 157.73% | Morgan Stanley | → $5 | Downgrades | Overweight → Equal-Weight |
| 08/18/2020 | — | Mizuho | Downgrades | Buy → Neutral | |
| 08/18/2020 | 157.73% | Citigroup | $31 → $5 | Downgrades | Buy → Neutral |
| 08/17/2020 | 106.19% | Roth Capital | $35 → $4 | Downgrades | Buy → Neutral |
| 07/28/2020 | 1704.12% | Roth Capital | → $35 | Initiates Coverage On | → Buy |
| 04/15/2020 | 570.1% | Morgan Stanley | $14 → $13 | Maintains | Overweight |
| 12/12/2019 | 930.93% | Cantor Fitzgerald | → $20 | Assumes | → Overweight |
| 03/07/2019 | 982.47% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 12/19/2018 | 1137.11% | Morgan Stanley | $25 → $24 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/16/2023 | — | Wedbush | 升级 | 中性 → 跑赢大盘 | |
| 11/14/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | 购买 → 购买 |
| 08/09/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | 购买 → 购买 |
| 06/26/2023 | 3.09% | Wedbush | 3 美元 → 2 美元 | 降级 | 跑赢大盘 → 中性 |
| 05/31/2023 | 415.46% | Roth MKM | → 10 美元 | 启动覆盖范围开启 | → 购买 |
| 05/26/2023 | 209.28% | 花旗集团 | 5 美元 → 6 美元 | 维护 | 买 |
| 05/10/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | → 购买 |
| 2023 年 4 月 25 日 | 54.64% | Wedbush | 5 美元 → 3 美元 | 维护 | 跑赢大盘 |
| 03/28/2023 | 209.28% | 瑞穗市 | 12 美元 → 6 美元 | 维护 | 买 |
| 03/28/2023 | 157.73% | Wedbush | 35 美元 → 5 美元 | 维护 | 跑赢大盘 |
| 03/28/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | → 购买 |
| 03/28/2023 | 157.73% | 花旗集团 | 15 美元 → 5 美元 | 维护 | 买 |
| 03/16/2023 | 1704.12% | Wedbush | → 35 美元 | 重申 | → 跑赢大盘 |
| 03/16/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | → 购买 |
| 02/15/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 维护 | 买 |
| 11/16/2022 | 518.56% | 瑞穗市 | 80 美元 → 12 美元 | 维护 | 买 |
| 11/09/2022 | 415.46% | HC Wainwright & Co. | 12 美元 → 10 美元 | 维护 | 买 |
| 11/02/2022 | 1755.67% | Wedbush | 4 美元 → 36 美元 | 维护 | 跑赢大盘 |
| 08/16/2022 | 312.37% | 瑞穗市 | 7 美元 → 8 美元 | 维护 | 买 |
| 08/15/2022 | 312.37% | 花旗集团 | 5 美元 → 8 美元 | 维护 | 买 |
| 05/17/2022 | 157.73% | 花旗集团 | 6 美元 → 5 美元 | 维护 | 买 |
| 2022 年 4 月 1 日 | 106.19% | 罗斯资本 | → 4 美元 | 升级 | 中性 → 买入 |
| 11/10/2021 | 260.82% | 瑞穗市 | 5 美元 → 7 美元 | 升级 | 中性 → 买入 |
| 2021 年 6 月 28 日 | — | 花旗集团 | 升级 | 卖出 → 买入 | |
| 06/07/2021 | 518.56% | HC Wainwright & Co. | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 08/18/2020 | 157.73% | 摩根士丹利 | → 5 美元 | 降级 | 超重 → 重量相等 |
| 08/18/2020 | — | 瑞穗市 | 降级 | 买入 → 中性 | |
| 08/18/2020 | 157.73% | 花旗集团 | 31 美元 → 5 美元 | 降级 | 买入 → 中性 |
| 2020 年 8 月 17 日 | 106.19% | 罗斯资本 | 35 美元 → 4 美元 | 降级 | 买入 → 中性 |
| 2020 年 7 月 28 日 | 1704.12% | 罗斯资本 | → 35 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 4 月 15 日 | 570.1% | 摩根士丹利 | 14 美元 → 13 美元 | 维护 | 超重 |
| 2019 年 12 月 12 日 | 930.93% | 坎托·菲茨杰拉德 | → 20 美元 | 假设 | → 超重 |
| 2019 年 7 月 3 日 | 982.47% | 坎托·菲茨杰拉德 | → 21 美元 | 启动覆盖范围开启 | → 超重 |
| 12/19/2018 | 1137.11% | 摩根士丹利 | 25 美元 → 24 美元 | 维护 | 超重 |
What is the target price for Unity Biotechnology (UBX)?
Unity Biotechnology (UBX) 的目标价格是多少？
The latest price target for Unity Biotechnology (NASDAQ: UBX) was reported by Wedbush on November 16, 2023. The analyst firm set a price target for $0.00 expecting UBX to fall to within 12 months (a possible -100.00% downside). 15 analyst firms have reported ratings in the last year.
Wedbush于2023年11月16日公布了Unity Biotechnology（纳斯达克股票代码：UBX）的最新目标股价。该分析公司将目标股价定为0.00美元，预计UBX将在12个月内跌至12个月内（可能下跌-100.00％）。去年有15家分析公司公布了评级。
What is the most recent analyst rating for Unity Biotechnology (UBX)?
分析师对Unity Biotechnology（UBX）的最新评级是多少？
The latest analyst rating for Unity Biotechnology (NASDAQ: UBX) was provided by Wedbush, and Unity Biotechnology upgraded their outperform rating.
Wedbush对Unity Biotechnology（纳斯达克股票代码：UBX）的最新分析师评级由Wedbush提供，Unity Biotechnolog
When is the next analyst rating going to be posted or updated for Unity Biotechnology (UBX)?
Unity Biotechnology（UBX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unity Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unity Biotechnology was filed on November 16, 2023 so you should expect the next rating to be made available sometime around November 16, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Unity Biotechnology的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Unity Biotechnology的最后一次评级是在2023年11月16日发布的，因此您应该预计下一个评级将在2024年11月16日左右公布。
Is the Analyst Rating Unity Biotechnology (UBX) correct?
分析师对Unity生物技术（UBX）的评级是否正确？
While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a upgraded with a price target of $0.00 to $0.00. The current price Unity Biotechnology (UBX) is trading at is $1.94, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Unity Biotechnology（UBX）评级已上调，目标股价为0.00美元至0.00美元。Unity Biotechnology（UBX）目前的交易价格为1.94美元，超出了分析师的预期区间。